middle.news
PainChek Unlocks US$3bn RTM Market with FDA-Backed Reimbursement Win
8:58am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
PainChek Unlocks US$3bn RTM Market with FDA-Backed Reimbursement Win
8:58am on Thursday 29th of January, 2026 AEDT
Key Points
FDA De Novo classification confirms PainChek as eligible for US RTM reimbursement
RTM framework offers monthly CMS reimbursements for musculoskeletal pain monitoring
PainChek uniquely assesses pain in non-verbal dementia patients in long-term care
US RTM market projected to reach US$3 billion annually by 2030
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PAINCHEK (ASX:PCK)
OPEN ARTICLE